It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
With a diverse network of substrates, NUDIX hydrolases have emerged as a key family of nucleotide-metabolizing enzymes. NUDT5 (also called NUDIX5) has been implicated in ADP-ribose and 8-oxo-guanine metabolism and was recently identified as a rheostat of hormone-dependent gene regulation and proliferation in breast cancer cells. Here, we further elucidate the physiological relevance of known NUDT5 substrates and underscore the biological requirement for NUDT5 in gene regulation and proliferation of breast cancer cells. We confirm the involvement of NUDT5 in ADP-ribose metabolism and dissociate a relationship to oxidized nucleotide sanitation. Furthermore, we identify potent NUDT5 inhibitors, which are optimized to promote maximal NUDT5 cellular target engagement by CETSA. Lead compound, TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells. We herein present TH5427 as a promising, targeted inhibitor that can be used to further study NUDT5 activity and ADP-ribose metabolism.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Wright, Roni H G 2 ; Wallner, Olov 1 ; Isaksson, Rebecka 1 ; Carter, Megan 3 ; Rudd, Sean G 1
; Loseva, Olga 1 ; Ann-Sofie Jemth 1 ; Almlöf, Ingrid 1 ; Font-Mateu, Jofre 2 ; Sabin Llona-Minguez 1
; Baranczewski, Pawel 4 ; Jeppsson, Fredrik 1 ; Homan, Evert 1 ; Almqvist, Helena 5 ; Axelsson, Hanna 5 ; Regmi, Shruti 5 ; Gustavsson, Anna-Lena 5 ; Lundbäck, Thomas 5 ; Scobie, Martin 1 ; Strömberg, Kia 1 ; Stenmark, Pål 3 ; Beato, Miguel 2 ; Helleday, Thomas 1 1 Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden
2 Centre de Regulació Genòmica (CRG), Barcelona Institute for Science and Technology, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain
3 Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden
4 Uppsala University Drug Optimization and Pharmaceutical Profiling Platform, Department of Pharmacy, Uppsala University, Uppsala, Sweden
5 Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden




